Literature DB >> 35030769

Mesoporous Platinum Nanotherapeutics for Combined Chemo-photothermal Cancer Treatment.

Wencong Zhao, Zhenhua Li, Hua Yang1, Cui Ren, Fangfang Lv, Shutao Gao2, Huanyun Ma3, Yi Jin3, Kun Ge, Dandan Liu, Jinchao Zhang, Huifang Liu.   

Abstract

Recently, nanoparticles that possess combined use in synergistic therapy, real-time imaging, and spatiotemporally controlled therapies have attracted enormous attention. Herein, we fabricated Doxorubicin (DOX)-loaded and β-cyclodextrin (β-CD)-capped mesoporous platinum nanoparticles (MPNPs) (DOX/MPNPs-AD-CD) for combined chemo-photothermal cancer therapy. DOX/MPNPs-AD-CD with high photothermal effect and loading rate could release the anticancer drugs stimulated by acidic tumor microenvironment or near-infrared light. Moreover, acid-degradable MPNPs would release cytotoxic Pt2+, which would enhance the efficiency of chemotherapy. In addition, the inherent photoacoustic and photothermal imaging can effectively guide chemo-photothermal therapy to achieve the desired treatment. Taken together, DOX/MPNPs-AD-CD possess the abilities of combined chemo-photothermal therapy and dual-imaging properties. The studies demonstrated that DOX/MPNPs-AD-CD could effectively inhibit tumor cell growth in vivo and in vitro. Thus, this treatment platform is expected to be one of interest for the clinical treatment of cancers.

Entities:  

Keywords:  DOX; chemotherapy; mesoporous platinum; nanoparticle; photothermal therapy

Year:  2019        PMID: 35030769     DOI: 10.1021/acsabm.9b00250

Source DB:  PubMed          Journal:  ACS Appl Bio Mater        ISSN: 2576-6422


  1 in total

Review 1.  Cyclodextrin-Based Nanoplatforms for Tumor Phototherapy: An Update.

Authors:  Xingjie Wu; Ying Chen; Qianqian Guo; Ling Tao; Yang Ding; Xianguang Ding; Xiangchun Shen
Journal:  Pharmaceutics       Date:  2022-06-29       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.